https://orcid.org/0000-0003-4770-8893
Citations (75)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Vincent Hartong & Arnold van Emmerik. (2023) Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study. Journal of Psychoactive Drugs 55:3, pages 310-320.
Read now
Read now
Carina S Peritore. (2022) The Promise of Psychedelic Research. Future Drug Discovery 4:1.
Read now
Read now
Coryn E. Mayer, Virginia T. LeBaron & Kimberly D. Acquaviva. (2022) Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions. Journal of Psychoactive Drugs 54:1, pages 81-92.
Read now
Read now
Monnica T. Williams, Alan K. Davis, Yitong Xin, Nathan D. Sepeda, Pamela Colón Grigas, Sinead Sinnott & Angela M. Haeny. (2021) People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs: Education, Prevention and Policy 28:3, pages 215-226.
Read now
Read now
Samuli Kangaslampi, Aino Hausen & Tarina Rauteenmaa. (2020) Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland. Journal of Psychoactive Drugs 52:4, pages 309-318.
Read now
Read now
Rafael L. Lancelotta & Alan K. Davis. (2020) Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects. Journal of Psychoactive Drugs 52:3, pages 273-281.
Read now
Read now
Elias Dakwar. (2019) Amphibious anti-depressants and other wonders. The American Journal of Drug and Alcohol Abuse 45:2, pages 115-116.
Read now
Read now
Articles from other publishers (68)
Bill Brennan & Alex Belser. 2024. EMBARK Psychedelic Therapy for Depression. EMBARK Psychedelic Therapy for Depression.
James Jonathan Rucker, Claire Roberts, Mathieu Seynaeve, Allan H. Young, Ben Suttle, Takahiro Yamamoto, Anna O. Ermakova, Fiona Dunbar & Frank Wiegand. (2024)
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
N,N
-dimethyltryptamine benzoate) in healthy participants
. Journal of Psychopharmacology.
Crossref
Crossref
Stephan C. Tap. (2024)
The potential of 5‐methoxy‐
N,N
‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
. Addiction Biology 29:4.
Crossref
Crossref
Caroline L Alves, Manuel Ciba, Thaise G L de O. Toutain, Joel Augusto Moura Porto, Eduardo Pondé de Sena, Christiane Thielemann & Francisco A Rodrigues. (2024) On the advances in machine learning and complex network measures to an EEG dataset from DMT experiments. Journal of Physics: Complexity 5:1, pages 015002.
Crossref
Crossref
Christopher Timmermann, Richard J. Zeifman, David Erritzoe, David J. Nutt & Robin L. Carhart-Harris. (2024) Effects of DMT on mental health outcomes in healthy volunteers. Scientific Reports 14:1.
Crossref
Crossref
Rubi Barman, Pranjit Kumar Bora, Jadumoni Saikia, Parthapratim Konwar, Aditya Sarkar, Phirose Kemprai, Siddhartha Proteem Saikia, Saikat Haldar, Adrian Slater & Dipanwita Banik. (2024) Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans. Phytochemistry 218, pages 113928.
Crossref
Crossref
Ninon Freidel, Liliane Kreuder, Brenden Samuel Rabinovitch, Frank Yizhao Chen, Ryan S. T. Huang & Evan Cole Lewis. (2024) Psychedelics, epilepsy, and seizures: a review. Frontiers in Pharmacology 14.
Crossref
Crossref
Yanying Chen, Tianyang Wang, Yuxi Tan & Duo Li. (2024) Feasibility and effectiveness study of applying a hallucinogen harm reduction and integration model to a mindfulness thinking intervention using virtual reality: A randomized controlled trial. DIGITAL HEALTH 10.
Crossref
Crossref
Oliver Rumle Hovmand, Emil Deleuran Poulsen & Sidse Arnfred. (2023) Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. Journal of Psychopharmacology 38:1, pages 19-32.
Crossref
Crossref
Stefan Paulus. (2023) Pharmaco-Analysis of Psychedelics—Philo-Fictions about New Materialism, Quantum Mechanics, Information Science, and the Philosophy of Immanence. Philosophies 9:1, pages 7.
Crossref
Crossref
Haley Maria Dourron, Charles D. Nichols, Otto Simonsson, Melissa Bradley, Robin Carhart-Harris & Peter S. Hendricks. (2023) 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?. Psychopharmacology.
Crossref
Crossref
Adam Wojtas. (2023) The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacological Reports 75:6, pages 1313-1325.
Crossref
Crossref
Anya Ragnhildstveit, Ryan Khan, Paul Seli, Lisa Claire Bass, River Jude August, Miriam Kaiyo, Nathaniel Barr, Laura Kate Jackson, Michael Santo Gaffrey, Joseph Peter Barsuglia & Lynnette Astrid Averill. (2023) 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study. Frontiers in Psychiatry 14.
Crossref
Crossref
Sarah J. Jefferson, Ian Gregg, Mark Dibbs, Clara Liao, Hao Wu, Pasha A. Davoudian, Samuel C. Woodburn, Patrick H. Wehrle, Jeffrey S. Sprouse, Alexander M. Sherwood, Alfred P. Kaye, Christopher Pittenger & Alex C. Kwan. (2023) 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology 48:9, pages 1257-1266.
Crossref
Crossref
Rabeet Tariq. (2023) Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms. Current Reviews in Clinical and Experimental Pharmacology 18:2, pages 94-109.
Crossref
Crossref
Lucas M. Friedberg, Abhishek K. Sen, Quynh Nguyen, Gabriel P. Tonucci, Elle B. Hellwarth, William J. GibbonsJr.Jr. & J. Andrew Jones. (2023) “In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E. coli”. Metabolic Engineering 78, pages 61-71.
Crossref
Crossref
Pascal Michael, David Luke & Oliver Robinson. (2023) This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience. Frontiers in Psychology 14.
Crossref
Crossref
Johannes T. Reckweg, Cees J. van Leeuwen, Cécile Henquet, Therese van Amelsvoort, Eef L. Theunissen, Natasha L. Mason, Riccardo Paci, Theis H. Terwey & Johannes G. Ramaekers. (2023) A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Frontiers in Psychiatry 14.
Crossref
Crossref
Maria Bălăeț, William Trender, Peter J. Hellyer & Adam Hampshire. (2023) Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic. Frontiers in Psychiatry 14.
Crossref
Crossref
Ahmed Al-Imam, Marek A. Motyka, Beata Hoffmann, Anita Magowska & Michal Michalak. (2023) Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”. Pharmaceuticals 16:6, pages 831.
Crossref
Crossref
Lilith Becher, Federico Nanni & Michael Koslowski. (2023) Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen. Nervenheilkunde 42:07/08, pages 450-458.
Crossref
Crossref
Azat Nasretdinov, Sebastian A. Barrientos, Ivani Brys, Pär Halje & Per Petersson. (2023) Systems-level analysis of local field potentials reveals differential effects of lysergic acid diethylamide and ketamine on neuronal activity and functional connectivity. Frontiers in Neuroscience 17.
Crossref
Crossref
Aki Nikolaidis, Rafaelle Lancelotta, Natalie Gukasyan, Roland R. Griffiths, Frederick S. Barrett & Alan K. Davis. (2023) Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders 324, pages 239-249.
Crossref
Crossref
Daniel Perkins, Simon G. D. Ruffell, Kimberley Day, Diego Pinzon Rubiano & Jerome Sarris. (2023) Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use. Frontiers in Neuroscience 16.
Crossref
Crossref
Luca Di Bartolomeo, Paolo Custurone, Natasha Irrera, Francesco Borgia, Federico Vaccaro, Francesco Squadrito & Mario Vaccaro. (2023) Vitiligo and Mental Health: Natural Compounds’ Usefulness. Antioxidants 12:1, pages 176.
Crossref
Crossref
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, Giulia Abate, Sara Anna Bonini, Gregorio Peron, Emanuela Tirelli, Mariachiara Pucci, Giovanni Ribaudo, Erika Oselladore, Marika Premoli, Alessandra Gianoncelli, Daniela Letizia Uberti & Maurizio Memo. (2023) The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. International Journal of Molecular Sciences 24:2, pages 1329.
Crossref
Crossref
Miriam Marguilho, Inês Figueiredo & Pedro Castro-Rodrigues. (2022) A unified model of ketamine’s dissociative and psychedelic properties. Journal of Psychopharmacology 37:1, pages 14-32.
Crossref
Crossref
Genaro Herrera Cano, Jordan Dean, Samuel Padilla Abreu, Amanda Hernández Rodríguez, Cyrena Abbasi, Madison Hinson & Brandon Lucke-Wold. (2022) Key Characteristics and Development of Psychoceuticals: A Review. International Journal of Molecular Sciences 23:24, pages 15777.
Crossref
Crossref
Ana María Ortiz Bernal, Charles L. Raison, Rafael L. Lancelotta & Alan K. Davis. (2022) Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Frontiers in Psychiatry 13.
Crossref
Crossref
Johanna Prugger, Ekin Derdiyok, Jannis Dinkelacker, Cyril Costines & Timo T. Schmidt. (2022) The Altered States Database: Psychometric data from a systematic literature review. Scientific Data 9:1.
Crossref
Crossref
Raúl López-Arnau, Jordi Camarasa, Marcel·lí Carbó, Núria Nadal-Gratacós, Pol Puigseslloses, María Espinosa-Velasco, Edurne Urquizu, Elena Escubedo & David Pubill. (2022) 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Frontiers in Psychiatry 13.
Crossref
Crossref
Haley Maria Dourron, Camilla Strauss & Peter S. Hendricks. (2022) Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. Pharmacological Reviews 74:4, pages 984-1029.
Crossref
Crossref
Matthias Forstmann & Christina Sagioglou. (2022) New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances. European Psychologist 27:4, pages 291-301.
Crossref
Crossref
Gavin P. Schmitz, Manish K. Jain, Samuel T. Slocum & Bryan L. Roth. (2022)
5-HT
2A
SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics
. ACS Chemical Neuroscience 13:16, pages 2386-2398.
Crossref
Crossref
Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, Hannes Kettner, Mendel Kaelen, Erik Lykke Mortensen, David John Nutt, Robin Lester Carhart-Harris & David Erritzoe. (2022) Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. Journal of Psychopharmacology 36:8, pages 932-942.
Crossref
Crossref
Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo, Alan K. Davis, Rafael Lancelotta, Natasha L. Mason & Johannes G. Ramaekers. (2022) The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT). Journal of Neurochemistry 162:1, pages 128-146.
Crossref
Crossref
V. L. Matrenitsky. (2022) РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ. Likarska sprava:3-4, pages 37-59.
Crossref
Crossref
Sam Gandy. (2022) Predictors and potentiators of psychedelic-occasioned mystical experiences. Journal of Psychedelic Studies 6:1, pages 31-47.
Crossref
Crossref
Hannes M Schwelm, Nicole Zimmermann, Tobias Scholl, Johannes Penner, Amy Autret, Volker Auwärter & Merja A Neukamm. (2022)
Qualitative and Quantitative Analysis of Tryptamines in the Poison of
Incilius alvarius
(Amphibia: Bufonidae)
. Journal of Analytical Toxicology 46:5, pages 540-548.
Crossref
Crossref
Edward James, Joachim Keppler, Thomas L Robertshaw & Ben Sessa. (2022) N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine. Human Psychopharmacology: Clinical and Experimental 37:3.
Crossref
Crossref
Henry Lowe, Ngeh Toyang, Blair Steele, Justin Grant, Amza Ali, Lorenzo Gordon & Wilfred Ngwa. (2022) Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Molecules 27:8, pages 2520.
Crossref
Crossref
Emilija Glavonic, Milos Mitic & Miroslav Adzic. (2022) Hallucinogenic drugs and their potential for treating fear‐related disorders: Through the lens of fear extinction. Journal of Neuroscience Research 100:4, pages 947-969.
Crossref
Crossref
Anna O Ermakova, Fiona Dunbar, James Rucker & Matthew W Johnson. (2021) A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology 36:3, pages 273-294.
Crossref
Crossref
Malin Vedøy Uthaug, Alan K Davis, Trevor Forrest Haas, Dawn Davis, Sean B Dolan, Rafael Lancelotta, Christopher Timmermann & Johannes G Ramaekers. (2021) The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology 36:3, pages 309-320.
Crossref
Crossref
Pratheek Mangini, Lynnette A. Averill & Alan K. Davis. (2022) Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. Journal of Psychedelic Studies 5:3, pages 149-155.
Crossref
Crossref
Johannes Reckweg, Natasha L. Mason, Cees van Leeuwen, Stefan W. Toennes, Theis H. Terwey & Johannes G. Ramaekers. (2021) A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. Frontiers in Pharmacology 12.
Crossref
Crossref
Xenia Gonda, Peter Dome, Joanna C. Neill & Frank I. Tarazi. (2021) Novel antidepressant drugs: Beyond monoamine targets. CNS Spectrums, pages 1-10.
Crossref
Crossref
Rubi Barman, Pranjit Kumar Bora, Jadumoni Saikia, Phirose Kemprai, Siddhartha Proteem Saikia, Saikat Haldar & Dipanwita Banik. (2021)
Nutmegs and wild nutmegs: An update on ethnomedicines, phytochemicals, pharmacology, and toxicity of the
Myristicaceae
species
. Phytotherapy Research 35:9, pages 4632-4659.
Crossref
Crossref
Gabrielle Agin-Liebes, Trevor F. Haas, Rafael Lancelotta, Malin V. Uthaug, Johannes G. Ramaekers & Alan K. Davis. (2021) Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology & Translational Science 4:2, pages 543-552.
Crossref
Crossref
Alan K Davis, Frederick S Barrett, Sara So, Natalie Gukasyan, Thomas C Swift & Roland R Griffiths. (2021) Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. Journal of Psychopharmacology 35:4, pages 437-446.
Crossref
Crossref
Duyen N. K. Pham, Andrew R. Chadeayne, James A. Golen & David R. Manke. (2021) Bufotenidinium iodide. IUCrData 6:2.
Crossref
Crossref
Alan K. Davis, Yitong Xin, Nathan D. Sepeda, Albert Garcia-Romeu & Monnica T. Williams. (2021) Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color. Chronic Stress 5, pages 247054702110356.
Crossref
Crossref
Fernanda Palhano-Fontes, Sérgio Mota-Rolim, Bruno Lobão-Soares, Nicole Galvão-Coelho, Joao Paulo Maia-Oliveira & Dráulio B. Araújo. 2021. Ayahuasca Healing and Science. Ayahuasca Healing and Science
21
41
.
Károly Kubicskó & Ödön Farkas. (2020)
Quantum chemical (QM:MM) investigation of the mechanism of enzymatic reaction of tryptamine and
N
,
N
-dimethyltryptamine with monoamine oxidase A
. Organic & Biomolecular Chemistry 18:47, pages 9660-9674.
Crossref
Crossref
Alexander M. Sherwood, Romain Claveau, Rafael Lancelotta, Kristi W. Kaylo & Kelsey Lenoch. (2020) Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use. ACS Omega 5:49, pages 32067-32075.
Crossref
Crossref
Richard J. Zeifman, Anne C. Wagner, Ros Watts, Hannes Kettner, Lea J. Mertens & Robin L. Carhart-Harris. (2020) Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation. Frontiers in Psychiatry 11.
Crossref
Crossref
Malin V. Uthaug, R. Lancelotta, A. M. Ortiz Bernal, A. K. Davis & Johannes G. Ramaekers. (2020) A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. Journal of Psychedelic Studies 4:2, pages 104-113.
Crossref
Crossref
Nathan D. Sepeda, John M. Clifton, Laura Y. Doyle, Rafael Lancelotta, Roland R. Griffiths & Alan K. Davis. (2020) Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies 4:2, pages 114-122.
Crossref
Crossref
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, Christopher C. Davoli & Alan K. Davis. (2020) Long-term effects of psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews 113, pages 179-189.
Crossref
Crossref
Jessica Winne, Barbara C. Boerner, Thawann Malfatti, Elis Brisa, Jhulimar Doerl, Ingrid Nogueira, Katarina E. Leão & Richardson N. Leão. (2020) Anxiety-like behavior induced by salicylate depends on age and can be prevented by a single dose of 5-MeO-DMT. Experimental Neurology 326, pages 113175.
Crossref
Crossref
Malin V Uthaug, Rafael Lancelotta, Attila Szabo, Alan K Davis, Jordi Riba & Johannes G Ramaekers. (2019) Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology 237:3, pages 773-785.
Crossref
Crossref
Lee E. Dunlap, Arya Azinfar, Calvin Ly, Lindsay P. Cameron, Jayashri Viswanathan, Robert J. Tombari, Douglas Myers-Turnbull, Jack C. Taylor, Ana Cristina Grodzki, Pamela J. Lein, David Kokel & David E. Olson. (2020)
Identification of Psychoplastogenic
N
,
N
-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure–Activity Relationship Studies
. Journal of Medicinal Chemistry 63:3, pages 1142-1155.
Crossref
Crossref
Alan K. Davis, Lynnette A. Averill, Nathan D. Sepeda, Joseph P. Barsuglia & Timothy Amoroso. (2020) Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress 4, pages 247054702093956.
Crossref
Crossref
Jacob S Aday, Emily K Bloesch & Christopher C Davoli. (2020) 2019: A year of expansion in psychedelic research, industry, and deregulation. Drug Science, Policy and Law 6, pages 205032452097448.
Crossref
Crossref
Alan K. Davis, Frederick S. Barrett & Roland R. Griffiths. (2020) Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science 15, pages 39-45.
Crossref
Crossref
Sam Gandy. (2019) Psychedelics and potential benefits in “healthy normals”: A review of the literature. Journal of Psychedelic Studies 3:3, pages 280-287.
Crossref
Crossref
Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths & Matthew W Johnson. (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33:9, pages 1088-1101.
Crossref
Crossref
M. V. Uthaug, R. Lancelotta, K. van Oorsouw, K. P. C. Kuypers, N. Mason, J. Rak, A. Šuláková, R. Jurok, M. Maryška, M. Kuchař, T. Páleníček, J. Riba & J. G. Ramaekers. (2019) A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology 236:9, pages 2653-2666.
Crossref
Crossref